Biological aging drives cellular dysfunction and human disease, yet studying human aging dynamics remains challenging due to limited experimental platforms. This study demonstrates that long-term post-mitotic culture of human fibroblasts can recapitulate and accelerate features of in vivo aging.
Researchers conducted longitudinal paired transcriptomic and epigenetic analyses of four female fibroblast lines. The findings revealed that in vitro aging reflects key signatures of in vivo primary fibroblast aging. This suggests that the aging process in cultured fibroblasts can serve as a model for understanding human aging.
Additionally, the direct neuronal conversion of in vitro-aged fibroblasts preserved biological age. This advancement enables pseudo-longitudinal modeling of neuronal aging through direct reprogramming, which could provide insights into the aging of neural cells.
Single-cell transcriptomics of in vitro-aging fibroblasts revealed a time-dependent increase in age-heterogeneity. This observation is consistent with previously reported age-associated heterogeneity driven by the variable loss of transcriptional programs in vivo.
Using this accelerated aging platform, the researchers evaluated anti-aging compounds. Metformin was found to broadly attenuate transcriptomic and epigenetic aging, while Rapamycin showed limited efficacy. These findings align with pre-clinical evidence and provide a platform to evaluate and predict therapeutic anti-aging compound efficacy at molecular resolution.
This system advances our understanding of aging mechanisms and facilitates the development of interventions against age-related diseases.
What this study does not show
This study does not provide evidence of clinical outcomes related to the use of anti-aging compounds in humans.
Evidence scorecard
- Evidence class: primary_research
- Human status: unclassified
- Publication type: Journal Article